Matthew P. Giannetti, MD, assistant professor, Harvard Medical School, Boston, Massachusetts, describes clonal and non-clonal mast cell activation disorders, and the relationship to the diagnosis of systemic mastocytosis. Dr Giannetti also reviews recent guideline updates that delineate the activation of mast cells as an acute event versus a chronic process.
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
